School of Biological Sciences, Centre for Medical and Molecular Bioscience, Illawarra Health and Medical Research Institute, University of Wollongong, New South Wales, Australia.
School of Chemistry, Centre for Medical and Molecular Bioscience, Illawarra Health and Medical Research Institute, University of Wollongong, New South Wales, Australia; Zernike Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands.
J Control Release. 2018 May 28;278:80-86. doi: 10.1016/j.jconrel.2018.03.022. Epub 2018 Mar 22.
Despite the longstanding existence of liposome technology in drug delivery applications, there have been no ligand-directed liposome formulations approved for clinical use to date. This lack of translation is due to several factors, one of which is the absence of molecular tools for the robust quantification of ligand density on the surface of liposomes. We report here for the first time the quantification of proteins attached to the surface of small unilamellar liposomes using single-molecule fluorescence imaging. Liposomes were surface-functionalized with fluorescently labeled human proteins previously validated to target the cancer cell surface biomarkers plasminogen activator inhibitor-2 (PAI-2) and trastuzumab (TZ, Herceptin®). These protein-conjugated liposomes were visualized using a custom-built wide-field fluorescence microscope with single-molecule sensitivity. By counting the photobleaching steps of the fluorescently labeled proteins, we calculated the number of attached proteins per liposome, which was 11 ± 4 proteins for single-ligand liposomes. Imaging of dual-ligand liposomes revealed stoichiometries of the two attached proteins in accordance with the molar ratios of protein added during preparation. Preparation of PAI-2/TZ dual-ligand liposomes via two different methods revealed that the post-insertion method generated liposomes with a more equal representation of the two differently sized proteins, demonstrating the ability of this preparation method to enable better control of liposome protein densities. We conclude that the single-molecule imaging method presented here is an accurate and reliable quantification tool for determining ligand density and stoichiometry on the surface of liposomes. This method has the potential to allow for comprehensive characterization of novel ligand-directed liposomes that should facilitate the translation of these nanotherapies through to the clinic.
尽管脂质体技术在药物输送应用中已经存在了很长时间,但迄今为止,还没有一种配体导向的脂质体制剂被批准用于临床应用。这种转化的缺乏是由于几个因素造成的,其中之一是缺乏用于在脂质体表面上进行配体密度的稳健定量的分子工具。我们在这里首次报告了使用单分子荧光成像技术定量附着在小单层脂质体表面的蛋白质。脂质体通过先前经过验证可靶向癌细胞表面生物标志物纤溶酶原激活物抑制剂-2 (PAI-2) 和曲妥珠单抗 (TZ,赫赛汀®) 的荧光标记的人蛋白进行表面功能化。使用具有单分子灵敏度的定制宽场荧光显微镜可以可视化这些蛋白缀合的脂质体。通过对荧光标记蛋白的光漂白步骤进行计数,我们计算了每个脂质体上附着的蛋白数量,对于单配体脂质体,这一数量为 11±4 个蛋白。对双配体脂质体的成像显示,与制备过程中添加的蛋白摩尔比一致,两个附着蛋白的化学计量比。通过两种不同方法制备 PAI-2/TZ 双配体脂质体,发现后插入法生成的脂质体中两种不同大小的蛋白的代表性更为均等,表明这种制备方法能够更好地控制脂质体蛋白密度。我们得出结论,这里提出的单分子成像方法是一种准确可靠的定量工具,可用于确定脂质体表面配体的密度和化学计量比。这种方法有可能允许对新型配体导向的脂质体进行全面表征,从而促进这些纳米疗法向临床的转化。